Consolidated Financial Statements Details - Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Intangible assets, net
Cost	$ 47,923	$ 26,115
Accumulated Amortization	3,167	206
Net Carrying Value	44,756	25,909
Projected amortization expense for the next five years
2026	3,567
2027	3,567
2028	3,567
2029	3,567
2030	3,567
Thereafter	26,921
Total	$ 44,756
Minimum
Intangible assets, net
Estimated remaining life of intangible assets	10 years 10 months 24 days
Maximum
Intangible assets, net
Estimated remaining life of intangible assets	19 years 10 months 24 days
Pulmokine - Seralutinib IP
Intangible assets, net
Cost	$ 26,115	26,115
Accumulated Amortization	2,383	206
Net Carrying Value	23,732	$ 25,909
BioInvent - Contract-based Intangible Asset
Intangible assets, net
Cost	20,725
Accumulated Amortization	780
Net Carrying Value	19,945
LAVA - Partnered Program IPs
Intangible assets, net
Cost	934
Accumulated Amortization	3
Net Carrying Value	931
LAVA-1266 IP
Intangible assets, net
Cost	149
Accumulated Amortization	1
Net Carrying Value	$ 148